secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001193125-25-142807
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics stockholders approve 3M share increase to 2017 Stock Incentive Plan at annual meeting
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2017 Plan increasing authorized shares by 3,000,000.
- Reelected Class II directors Frank E. Thomas, Patrick Vink, M.D., and Esther Rajavelu to 2028 meeting.
- Ratified PricewaterhouseCoopers as independent auditor for fiscal year 2025.
- Advisory vote on executive compensation passed with 25.2M for, 0.6M against.
- Quorum of 40,015,633 shares (71.57%) present at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525142807/0001193125-25-142807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525142807/d934847d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-142807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer